focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility

Fri, 28th Oct 2022 21:18

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Tullow Oil PLC - London-based oil and gas exploration company - and Capricorn Energy PLC - Edinburgh-based oil and gas exploration and development company - Confirm that they will no longer proceed with a combination. The Takeover Panel has consented to the withdrawal of Tullow's associated offer. At end of September, Tullow set out plans to terminate its co-operation deal with Capricorn Energy PLC, after Capricorn proposed a merger with NewMed Energy Ltd. Capricorn also withdrew its recommendation for the previously agreed combination with Tullow.

----------

Inspecs Group PLC - Bath, England-based eyewear company - Chief Executive Officer Robin Christian Bjorn Totterman buys 378,376 shares at 52.47 pence each, totalling around GBP198,534.

----------

Kropz PLC - African phosphate developer - Enters into a new bridge loan facility of ZAR126 million, or GBP6.0 million, with its major shareholder, the ARC Fund, to meet immediate cash requirements due to delays in the ramp-up of operations at Kropz Elandsfontein Pty Ltd.

----------

Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Allots and issues a total of 4.8 million new ordinary shares of 5 pence each in Diurnal. This follows the court sanctioning the scheme in relation to the recommended cash offer by Neurocrine Biosciences Inc.

----------

Upland Resources Ltd - London-based oil and gas company - Pretax loss in the year which ended June 30 narrows to GBP494,295 versus GBP789,892 a year ago. Administrative expenses drop to GBP354,828 from GBP570,676. Registers an intangible asset impairment cost of GBP219,216 in the prior period. Records no revenue in the period, unchanged from a year before.

----------

Umuthi Healthcare Solutions PLC - London-based healthcare firm - Loss from operating activities in the six months to August 31 narrows to GBP6,329 from GBP82,500, year-on-year. Administrative expenses fall to GBP6,329 from GBP82,500. Records no revenue, unchanged from a year before.

----------

ADM Energy PLC - London-based natural resource investor - Raises GBP500,000 net through the issue of 41.7 million new ordinary shares to Tennessee Black Gold at a subscription price of 1.2 pence per share. The shares will represent 14% of its enlarged issued share capital. Says its subscriber has also agreed to provide the company with a loan facility of USD250,000, to be advanced in five monthly instalments of USD50,000 each.

----------

BlueRock Diamonds PLC - Reading-based diamond producer focused on South Africa - In the third quarter of 2022, produces 195,848 tonnes from its Kareevlei diamond mine in South Africa, up 23% versus 159,867t a year before. Sells 5,475 carats, down 21% from 6,887 carats quarter-on-quarter. "In order to adhere to the mining plan there was a significant increase in activity related to stripping, waste mined and movement of stockpiles," CEO Victor Dingle says. Revises its guidance for 2022 and 2023 to reflect the outcome of a high-level review undertaken of the production and mining plan and continued uncertainty over production and grade. Expects to 600,000t to 700,000t processed, down from 620,000t to 670,000t.

----------

Golden Prospect Precious Metals Ltd - investment fund - Pretax loss widens in the six months to June 30 to GBP9.4 million from GBP9.2 million a year ago. Fair value through loss widens to GBP8.9 million from GBP8.8 million. Records no income, unchanged from a year before.

----------

Bidstack Group PLC - London-based in-game advertising platform - Notes recent press commentary regarding a private communication by the company "with certain investors" concerning an email received from Azerion. Says contrary to the press commentary, there is no litigation with Azerion, and the contract with Azerion continues to operate as expected.

----------

SulNOx Group PLC - London-based supplier of fuel conditioners - Pretax loss in the six months to September 30 widens to GBP964,702 versus GBP724,121 a year before, as administrative expenses jump to GBP975,069 from GBP723,718. Revenue triples to GBP74,805 from GBP24,486. Says it is starting to see "significant traction" in the sales of its SulNOxEco Fuel Conditioner product. Says revenue pipeline is strong and diversified by geography and industry.

----------

MAC Alpha Ltd - acquisition vehicle listed on LSE - Records a pretax loss of GBP266,043 in the period from incorporation on October 11 to June 30. Registers administrative expenses of GBP266,043.

----------

Marwyn Acquisition Co III Ltd - acquisition vehicle - Pretax loss in the year to June 30 widens to GBP1.1 million from GBP636,141, year-on-year. Records a GBP254,000 movement in the fair value of warrants. Administrative expenses rise to GBP892,233 versus GBP636,141. Records no revenue, unchanged from a year before. Remains confident in delivering its strategy and creating significant value for its shareholders.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
10 Jan 2019 11:33

Diurnal Shares Surge As Secures Second Patent For Chronocort In US

LONDON (Alliance News) - Diurnal Group PLC on Thursday said the US Patent & Trademark Office has granted the company a second US patent for Chronocort.Diurnal shares almost tripled on a

Read more
10 Jan 2019 11:26

Diurnal awarded US patent for Chronocort product

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified release hydrocortisone product.

Read more
17 Oct 2018 12:10

Diurnal halts US development of Chronocort after European trials come up short

(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a recent phase-three European trial.

Read more
17 Oct 2018 10:41

Diurnal Puts All Chronocort US Development Activities On Hold

LONDON (Alliance News) - Diurnal Group PLC said Wednesday it decided to put all US development activities for its Chronocort product on hold, after it failed to meet its primary objective in its a

Read more
8 Oct 2018 17:07

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news from 10 Downing Street there remains "big in of

Read more
8 Oct 2018 15:15

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment of young children with adrenal insufficiency to

Read more
8 Oct 2018 12:00

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a 3%

Read more
8 Oct 2018 10:33

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%. The asset manager confirmed it is in to

Read more
8 Oct 2018 09:29

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.

Read more
8 Oct 2018 08:54

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP

Read more
8 Oct 2018 07:48

LONDON MARKET PRE-OPEN: Lower Call; Schroders Confirms Lloyds Talks

LONDON (Alliance News) - Stocks in London on Monday are set to continue last week's slide, fuelled by concerns that strong US economic data will lead to a quickened pace of interest rate hikes.In

Read more
5 Oct 2018 09:20

Diurnal kicks off adrenal condition trial with first patients

(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).

Read more
5 Oct 2018 08:16

Diurnal Enrols First Patients In Phase Three US Chronocort Trial

LONDON (Alliance News) - Pharmaceutical company Diurnal Group PLC on Friday said the first two patients have been enrolled into its phase three US trial of Chronocort.Chronocort is a form a

Read more
20 Sep 2018 09:56

Diurnal Generates First Revenue But Loss Deepens As Costs Rise

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Thursday its annual loss deepened amid higher costs despite generating its first revenue from drug sales.For the year the

Read more
15 Aug 2018 12:39

German Body Says Diurnal Alkindi's Benefit Over Generic Not Proven

LONDON (Alliance News) - Diurnal Group PLC said Wednesday a German body published a study which says that the benefit of the company's product Alkindi over generic hydrocortisone has not been

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.